Regeneration of intestinal stem/progenitor cells following doxorubicin treatment of mice.
Ontology highlight
ABSTRACT: The intestinal epithelium is in a constant state of renewal. The rapid turnover of cells is fed by a hierarchy of transit amplifying and stem/progenitor cells destined to give rise to the four differentiated epithelial lineages of the small intestine. Doxorubicin (Dox) is a commonly used chemotherapeutic agent that preferentially induces apoptosis in the intestinal stem cell zone (SCZ). We hypothesized that Dox treatment would initially decrease "+4" intestinal stem cell numbers with a subsequent expansion during mucosal repair. Temporal assessment following Dox treatment demonstrated rapid induction of apoptosis in the SCZ leading to a decrease in the number of intestinal stem/progenitor cells as determined by flow cytometry for CD45(-) SP cells, and immunohistochemistry of cells positive
SUBMITTER: Dekaney CM
PROVIDER: S-EPMC2739827 | biostudies-literature | 2009 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA